| Bioactivity | Arg-Gly-Glu-Ser TFA is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets. | ||||||
| In Vivo | Arg-Gly-Glu-Ser (5 mg/kg) in combination with LPS or saline + RGDS does not affect neutrophil and macrophage cell numbers and has no effect on protein accumulation compared with LPS- or saline-treated mice, respectively[1]. | ||||||
| Name | Arg-Gly-Glu-Ser TFA | ||||||
| Sequence | Arg-Gly-Glu-Ser | ||||||
| Shortening | RGES | ||||||
| Formula | C18H30F3N7O10 | ||||||
| Molar Mass | 561.47 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||
| Reference | [1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18. |
Arg-Gly-Glu-Ser TFA
CAS: F: C18H30F3N7O10 W: 561.47
Arg-Gly-Glu-Ser TFA is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to acti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.